CADTH has completed a project to inform decision-makers about the appropriate use of testing for DNA mismatch repair deficiency (dMMR). The health technology assessment addresses policy issues including the appropriate populations for dMMR testing for identifying new families with a hereditary predisposition to certain cancers (Lynch syndrome) and for predicting the response to chemotherapy. These issues are addressed by evaluating the diagnostic accuracy, clinical utility, and cost-effectiveness of dMMR testing in a universal testing scenario, as well as within specific subpopulations (for example, based on age or family history). Patient preferences and experiences and the ethical implications of dMMR testing are also addressed.
The project has four key components:
- Science report
- Ethics report